nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—Everolimus—kidney cancer	0.123	0.293	CbGbCtD
Hydralazine—CYP3A4—Temsirolimus—kidney cancer	0.0831	0.198	CbGbCtD
Hydralazine—CYP3A4—Pazopanib—kidney cancer	0.0437	0.104	CbGbCtD
Hydralazine—CYP3A4—Erlotinib—kidney cancer	0.0312	0.0741	CbGbCtD
Hydralazine—CYP3A4—Paclitaxel—kidney cancer	0.0285	0.0678	CbGbCtD
Hydralazine—CYP3A4—Sorafenib—kidney cancer	0.0253	0.0603	CbGbCtD
Hydralazine—CYP3A4—Vinblastine—kidney cancer	0.025	0.0595	CbGbCtD
Hydralazine—CYP3A4—Vincristine—kidney cancer	0.0246	0.0585	CbGbCtD
Hydralazine—CYP3A4—Sunitinib—kidney cancer	0.0205	0.0488	CbGbCtD
Hydralazine—CYP3A4—Doxorubicin—kidney cancer	0.0154	0.0366	CbGbCtD
Hydralazine—RYR2—cardiac atrium—kidney cancer	0.0124	0.12	CbGeAlD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CNN2—kidney cancer	0.0111	0.126	CbGpPWpGaD
Hydralazine—AOC3—nephron tubule—kidney cancer	0.0092	0.0885	CbGeAlD
Hydralazine—RYR2—Stimuli-sensing channels—RYR1—kidney cancer	0.00862	0.0977	CbGpPWpGaD
Hydralazine—AOC3—renal system—kidney cancer	0.00837	0.0804	CbGeAlD
Hydralazine—AOC3—kidney—kidney cancer	0.00809	0.0777	CbGeAlD
Hydralazine—AOC3—cortex of kidney—kidney cancer	0.00788	0.0757	CbGeAlD
Hydralazine—AOC3—gonad—kidney cancer	0.0075	0.0721	CbGeAlD
Hydralazine—AOC3—cardiac atrium—kidney cancer	0.00749	0.072	CbGeAlD
Hydralazine—P4HA1—nephron tubule—kidney cancer	0.00736	0.0707	CbGeAlD
Hydralazine—CYP3A4—urine—kidney cancer	0.00725	0.0696	CbGeAlD
Hydralazine—P4HA1—renal system—kidney cancer	0.00669	0.0643	CbGeAlD
Hydralazine—P4HA1—cortex of kidney—kidney cancer	0.0063	0.0605	CbGeAlD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—RYR1—kidney cancer	0.00601	0.0681	CbGpPWpGaD
Hydralazine—P4HA1—gonad—kidney cancer	0.006	0.0576	CbGeAlD
Hydralazine—P4HA1—cardiac atrium—kidney cancer	0.00599	0.0576	CbGeAlD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—RYR1—kidney cancer	0.00582	0.066	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—RYR1—kidney cancer	0.00562	0.0637	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GJB1—kidney cancer	0.00398	0.0451	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNA1—kidney cancer	0.00368	0.0418	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CALD1—kidney cancer	0.00349	0.0396	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—ATP7B—kidney cancer	0.00323	0.0366	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.00247	0.028	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ITPR2—kidney cancer	0.00232	0.0263	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—ITPR2—kidney cancer	0.00225	0.0255	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL13—kidney cancer	0.00208	0.0235	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.00196	0.0222	CbGpPWpGaD
Hydralazine—CYP3A4—renal system—kidney cancer	0.00177	0.017	CbGeAlD
Hydralazine—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.00174	0.0198	CbGpPWpGaD
Hydralazine—CYP3A4—kidney—kidney cancer	0.00171	0.0165	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.00157	0.0178	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNB1—kidney cancer	0.00119	0.0135	CbGpPWpGaD
Hydralazine—RYR2—Stimuli-sensing channels—RAF1—kidney cancer	0.00113	0.0128	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.00112	0.0127	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.00112	0.0127	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.00112	0.0127	CbGpPWpGaD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.0011	0.0124	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.0011	0.0124	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000795	0.00901	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000736	0.00834	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—RAF1—kidney cancer	0.000735	0.00833	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—JUN—kidney cancer	0.000664	0.00753	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—JUN—kidney cancer	0.00066	0.00749	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.000655	0.00743	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000625	0.00708	CbGpPWpGaD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.000616	0.00699	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000593	0.00672	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.000577	0.00654	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000572	0.00649	CbGpPWpGaD
Hydralazine—Dysuria—Capecitabine—kidney cancer	0.000505	0.0013	CcSEcCtD
Hydralazine—Neutropenia—Capecitabine—kidney cancer	0.000505	0.0013	CcSEcCtD
Hydralazine—Decreased appetite—Sorafenib—kidney cancer	0.000503	0.0013	CcSEcCtD
Hydralazine—Anorexia—Dactinomycin—kidney cancer	0.000503	0.0013	CcSEcCtD
Hydralazine—Nausea—Pazopanib—kidney cancer	0.000502	0.0013	CcSEcCtD
Hydralazine—Paraesthesia—Sunitinib—kidney cancer	0.0005	0.00129	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.0005	0.00129	CcSEcCtD
Hydralazine—Dyspnoea—Sunitinib—kidney cancer	0.000497	0.00128	CcSEcCtD
Hydralazine—Constipation—Sorafenib—kidney cancer	0.000495	0.00128	CcSEcCtD
Hydralazine—Malaise—Gemcitabine—kidney cancer	0.000494	0.00127	CcSEcCtD
Hydralazine—Hypersensitivity—Vinblastine—kidney cancer	0.000493	0.00127	CcSEcCtD
Hydralazine—Myalgia—Vincristine—kidney cancer	0.000492	0.00127	CcSEcCtD
Hydralazine—Hypersensitivity—Everolimus—kidney cancer	0.000491	0.00127	CcSEcCtD
Hydralazine—Dyspepsia—Sunitinib—kidney cancer	0.00049	0.00127	CcSEcCtD
Hydralazine—Leukopenia—Gemcitabine—kidney cancer	0.00049	0.00127	CcSEcCtD
Hydralazine—Flushing—Paclitaxel—kidney cancer	0.000489	0.00126	CcSEcCtD
Hydralazine—Weight decreased—Capecitabine—kidney cancer	0.000489	0.00126	CcSEcCtD
Hydralazine—Decreased appetite—Sunitinib—kidney cancer	0.000484	0.00125	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000481	0.00124	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000481	0.00124	CcSEcCtD
Hydralazine—Depression—Capecitabine—kidney cancer	0.00048	0.00124	CcSEcCtD
Hydralazine—Constipation—Sunitinib—kidney cancer	0.000476	0.00123	CcSEcCtD
Hydralazine—Chills—Paclitaxel—kidney cancer	0.000473	0.00122	CcSEcCtD
Hydralazine—Lymphadenopathy—Doxorubicin—kidney cancer	0.000472	0.00122	CcSEcCtD
Hydralazine—Neuropathy peripheral—Capecitabine—kidney cancer	0.000472	0.00122	CcSEcCtD
Hydralazine—Pruritus—Everolimus—kidney cancer	0.000472	0.00122	CcSEcCtD
Hydralazine—Oedema—Vincristine—kidney cancer	0.000471	0.00122	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000471	0.00534	CbGpPWpGaD
Hydralazine—Jaundice—Capecitabine—kidney cancer	0.000469	0.00121	CcSEcCtD
Hydralazine—Conjunctivitis—Capecitabine—kidney cancer	0.000468	0.00121	CcSEcCtD
Hydralazine—Arthralgia—Gemcitabine—kidney cancer	0.000466	0.0012	CcSEcCtD
Hydralazine—Myalgia—Gemcitabine—kidney cancer	0.000466	0.0012	CcSEcCtD
Hydralazine—Thrombocytopenia—Vincristine—kidney cancer	0.000461	0.00119	CcSEcCtD
Hydralazine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000461	0.00119	CcSEcCtD
Hydralazine—Discomfort—Gemcitabine—kidney cancer	0.000461	0.00119	CcSEcCtD
Hydralazine—Urticaria—Sorafenib—kidney cancer	0.00046	0.00119	CcSEcCtD
Hydralazine—Haematuria—Capecitabine—kidney cancer	0.000459	0.00119	CcSEcCtD
Hydralazine—Decreased appetite—Dactinomycin—kidney cancer	0.000458	0.00118	CcSEcCtD
Hydralazine—Diarrhoea—Vinblastine—kidney cancer	0.000458	0.00118	CcSEcCtD
Hydralazine—Body temperature increased—Sorafenib—kidney cancer	0.000458	0.00118	CcSEcCtD
Hydralazine—Diarrhoea—Everolimus—kidney cancer	0.000456	0.00118	CcSEcCtD
Hydralazine—Pruritus—Erlotinib—kidney cancer	0.000455	0.00118	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000452	0.00512	CbGpPWpGaD
Hydralazine—Vascular purpura—Doxorubicin—kidney cancer	0.00045	0.00116	CcSEcCtD
Hydralazine—Agranulocytosis—Capecitabine—kidney cancer	0.000449	0.00116	CcSEcCtD
Hydralazine—Anorexia—Vincristine—kidney cancer	0.000449	0.00116	CcSEcCtD
Hydralazine—Oedema—Gemcitabine—kidney cancer	0.000447	0.00115	CcSEcCtD
Hydralazine—Cardiac failure congestive—Doxorubicin—kidney cancer	0.000444	0.00115	CcSEcCtD
Hydralazine—Dizziness—Vinblastine—kidney cancer	0.000443	0.00114	CcSEcCtD
Hydralazine—Dizziness—Everolimus—kidney cancer	0.000441	0.00114	CcSEcCtD
Hydralazine—Muscle spasms—Paclitaxel—kidney cancer	0.000441	0.00114	CcSEcCtD
Hydralazine—Body temperature increased—Sunitinib—kidney cancer	0.00044	0.00114	CcSEcCtD
Hydralazine—Diarrhoea—Erlotinib—kidney cancer	0.00044	0.00114	CcSEcCtD
Hydralazine—Hypotension—Vincristine—kidney cancer	0.00044	0.00114	CcSEcCtD
Hydralazine—Thrombocytopenia—Gemcitabine—kidney cancer	0.000438	0.00113	CcSEcCtD
Hydralazine—Renal failure acute—Doxorubicin—kidney cancer	0.000436	0.00113	CcSEcCtD
Hydralazine—Feeling abnormal—Dactinomycin—kidney cancer	0.000435	0.00112	CcSEcCtD
Hydralazine—Hepatitis—Capecitabine—kidney cancer	0.000432	0.00112	CcSEcCtD
Hydralazine—Hypoaesthesia—Capecitabine—kidney cancer	0.00043	0.00111	CcSEcCtD
Hydralazine—Tremor—Paclitaxel—kidney cancer	0.00043	0.00111	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000429	0.00111	CcSEcCtD
Hydralazine—Hypersensitivity—Sorafenib—kidney cancer	0.000427	0.0011	CcSEcCtD
Hydralazine—Anorexia—Gemcitabine—kidney cancer	0.000426	0.0011	CcSEcCtD
Hydralazine—Vomiting—Vinblastine—kidney cancer	0.000426	0.0011	CcSEcCtD
Hydralazine—Dizziness—Erlotinib—kidney cancer	0.000426	0.0011	CcSEcCtD
Hydralazine—Ill-defined disorder—Paclitaxel—kidney cancer	0.000426	0.0011	CcSEcCtD
Hydralazine—Vomiting—Everolimus—kidney cancer	0.000424	0.00109	CcSEcCtD
Hydralazine—Anaemia—Paclitaxel—kidney cancer	0.000424	0.00109	CcSEcCtD
Hydralazine—Paraesthesia—Vincristine—kidney cancer	0.000423	0.00109	CcSEcCtD
Hydralazine—Agitation—Paclitaxel—kidney cancer	0.000421	0.00109	CcSEcCtD
Hydralazine—Rash—Everolimus—kidney cancer	0.000421	0.00109	CcSEcCtD
Hydralazine—Dermatitis—Everolimus—kidney cancer	0.00042	0.00108	CcSEcCtD
Hydralazine—Headache—Vinblastine—kidney cancer	0.000419	0.00108	CcSEcCtD
Hydralazine—Purpura—Doxorubicin—kidney cancer	0.000418	0.00108	CcSEcCtD
Hydralazine—Headache—Everolimus—kidney cancer	0.000418	0.00108	CcSEcCtD
Hydralazine—Hypotension—Gemcitabine—kidney cancer	0.000418	0.00108	CcSEcCtD
Hydralazine—Body temperature increased—Dactinomycin—kidney cancer	0.000417	0.00108	CcSEcCtD
Hydralazine—Malaise—Paclitaxel—kidney cancer	0.000414	0.00107	CcSEcCtD
Hydralazine—Cardiac failure—Doxorubicin—kidney cancer	0.000413	0.00107	CcSEcCtD
Hydralazine—Leukopenia—Paclitaxel—kidney cancer	0.000411	0.00106	CcSEcCtD
Hydralazine—Hypersensitivity—Sunitinib—kidney cancer	0.00041	0.00106	CcSEcCtD
Hydralazine—Decreased appetite—Vincristine—kidney cancer	0.00041	0.00106	CcSEcCtD
Hydralazine—Pruritus—Sorafenib—kidney cancer	0.00041	0.00106	CcSEcCtD
Hydralazine—Vomiting—Erlotinib—kidney cancer	0.000409	0.00106	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000407	0.00105	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000407	0.00105	CcSEcCtD
Hydralazine—Rash—Erlotinib—kidney cancer	0.000406	0.00105	CcSEcCtD
Hydralazine—Dermatitis—Erlotinib—kidney cancer	0.000405	0.00105	CcSEcCtD
Hydralazine—Palpitations—Paclitaxel—kidney cancer	0.000405	0.00105	CcSEcCtD
Hydralazine—Headache—Erlotinib—kidney cancer	0.000403	0.00104	CcSEcCtD
Hydralazine—Constipation—Vincristine—kidney cancer	0.000403	0.00104	CcSEcCtD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000403	0.00457	CbGpPWpGaD
Hydralazine—Paraesthesia—Gemcitabine—kidney cancer	0.000401	0.00104	CcSEcCtD
Hydralazine—Flushing—Capecitabine—kidney cancer	0.000401	0.00104	CcSEcCtD
Hydralazine—Dyspnoea—Gemcitabine—kidney cancer	0.000399	0.00103	CcSEcCtD
Hydralazine—Nausea—Vinblastine—kidney cancer	0.000398	0.00103	CcSEcCtD
Hydralazine—Nausea—Everolimus—kidney cancer	0.000396	0.00102	CcSEcCtD
Hydralazine—Diarrhoea—Sorafenib—kidney cancer	0.000396	0.00102	CcSEcCtD
Hydralazine—Pruritus—Sunitinib—kidney cancer	0.000394	0.00102	CcSEcCtD
Hydralazine—Myalgia—Paclitaxel—kidney cancer	0.00039	0.00101	CcSEcCtD
Hydralazine—Arthralgia—Paclitaxel—kidney cancer	0.00039	0.00101	CcSEcCtD
Hydralazine—Anxiety—Paclitaxel—kidney cancer	0.000389	0.001	CcSEcCtD
Hydralazine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000389	0.00441	CbGpPWpGaD
Hydralazine—Decreased appetite—Gemcitabine—kidney cancer	0.000389	0.001	CcSEcCtD
Hydralazine—Hypersensitivity—Dactinomycin—kidney cancer	0.000389	0.001	CcSEcCtD
Hydralazine—Chills—Capecitabine—kidney cancer	0.000388	0.001	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000386	0.000996	CcSEcCtD
Hydralazine—Discomfort—Paclitaxel—kidney cancer	0.000386	0.000996	CcSEcCtD
Hydralazine—Dizziness—Sorafenib—kidney cancer	0.000383	0.000988	CcSEcCtD
Hydralazine—Constipation—Gemcitabine—kidney cancer	0.000382	0.000987	CcSEcCtD
Hydralazine—Nausea—Erlotinib—kidney cancer	0.000382	0.000987	CcSEcCtD
Hydralazine—Diarrhoea—Sunitinib—kidney cancer	0.000381	0.000984	CcSEcCtD
Hydralazine—Oedema—Paclitaxel—kidney cancer	0.000374	0.000966	CcSEcCtD
Hydralazine—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000373	0.00423	CbGpPWpGaD
Hydralazine—Body temperature increased—Vincristine—kidney cancer	0.000373	0.000961	CcSEcCtD
Hydralazine—Dizziness—Sunitinib—kidney cancer	0.000368	0.000951	CcSEcCtD
Hydralazine—Feeling abnormal—Gemcitabine—kidney cancer	0.000368	0.000951	CcSEcCtD
Hydralazine—Vomiting—Sorafenib—kidney cancer	0.000368	0.00095	CcSEcCtD
Hydralazine—Thrombocytopenia—Paclitaxel—kidney cancer	0.000366	0.000946	CcSEcCtD
Hydralazine—Tachycardia—Paclitaxel—kidney cancer	0.000365	0.000943	CcSEcCtD
Hydralazine—Rash—Sorafenib—kidney cancer	0.000365	0.000942	CcSEcCtD
Hydralazine—Dermatitis—Sorafenib—kidney cancer	0.000365	0.000941	CcSEcCtD
Hydralazine—Headache—Sorafenib—kidney cancer	0.000363	0.000936	CcSEcCtD
Hydralazine—Muscle spasms—Capecitabine—kidney cancer	0.000362	0.000934	CcSEcCtD
Hydralazine—Diarrhoea—Dactinomycin—kidney cancer	0.000361	0.000931	CcSEcCtD
Hydralazine—Anorexia—Paclitaxel—kidney cancer	0.000357	0.000921	CcSEcCtD
Hydralazine—Vomiting—Sunitinib—kidney cancer	0.000354	0.000914	CcSEcCtD
Hydralazine—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000354	0.00401	CbGpPWpGaD
Hydralazine—Body temperature increased—Gemcitabine—kidney cancer	0.000353	0.000912	CcSEcCtD
Hydralazine—Tremor—Capecitabine—kidney cancer	0.000353	0.00091	CcSEcCtD
Hydralazine—Rash—Sunitinib—kidney cancer	0.000351	0.000907	CcSEcCtD
Hydralazine—Dermatitis—Sunitinib—kidney cancer	0.000351	0.000906	CcSEcCtD
Hydralazine—Hypotension—Paclitaxel—kidney cancer	0.00035	0.000903	CcSEcCtD
Hydralazine—Ill-defined disorder—Capecitabine—kidney cancer	0.000349	0.000901	CcSEcCtD
Hydralazine—Headache—Sunitinib—kidney cancer	0.000349	0.000901	CcSEcCtD
Hydralazine—Anaemia—Capecitabine—kidney cancer	0.000348	0.000898	CcSEcCtD
Hydralazine—Hypersensitivity—Vincristine—kidney cancer	0.000347	0.000896	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—kidney cancer	0.000345	0.00089	CcSEcCtD
Hydralazine—Nausea—Sorafenib—kidney cancer	0.000344	0.000888	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000341	0.00088	CcSEcCtD
Hydralazine—Malaise—Capecitabine—kidney cancer	0.000339	0.000876	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—kidney cancer	0.000339	0.000875	CcSEcCtD
Hydralazine—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000339	0.00384	CbGpPWpGaD
Hydralazine—Leukopenia—Capecitabine—kidney cancer	0.000337	0.000869	CcSEcCtD
Hydralazine—Paraesthesia—Paclitaxel—kidney cancer	0.000336	0.000867	CcSEcCtD
Hydralazine—Vomiting—Dactinomycin—kidney cancer	0.000335	0.000866	CcSEcCtD
Hydralazine—Dyspnoea—Paclitaxel—kidney cancer	0.000334	0.000861	CcSEcCtD
Hydralazine—Palpitations—Capecitabine—kidney cancer	0.000333	0.000858	CcSEcCtD
Hydralazine—Rash—Dactinomycin—kidney cancer	0.000333	0.000858	CcSEcCtD
Hydralazine—Nausea—Sunitinib—kidney cancer	0.000331	0.000854	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—kidney cancer	0.000331	0.000853	CcSEcCtD
Hydralazine—Dyspepsia—Paclitaxel—kidney cancer	0.000329	0.00085	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—kidney cancer	0.000326	0.00084	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—kidney cancer	0.000326	0.00084	CcSEcCtD
Hydralazine—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000325	0.00369	CbGpPWpGaD
Hydralazine—Decreased appetite—Paclitaxel—kidney cancer	0.000325	0.00084	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000323	0.000834	CcSEcCtD
Hydralazine—Diarrhoea—Vincristine—kidney cancer	0.000322	0.000832	CcSEcCtD
Hydralazine—Myalgia—Capecitabine—kidney cancer	0.00032	0.000827	CcSEcCtD
Hydralazine—Arthralgia—Capecitabine—kidney cancer	0.00032	0.000827	CcSEcCtD
Hydralazine—Constipation—Paclitaxel—kidney cancer	0.00032	0.000826	CcSEcCtD
Hydralazine—Anxiety—Capecitabine—kidney cancer	0.000319	0.000824	CcSEcCtD
Hydralazine—Discomfort—Capecitabine—kidney cancer	0.000317	0.000817	CcSEcCtD
Hydralazine—Pruritus—Gemcitabine—kidney cancer	0.000316	0.000816	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—kidney cancer	0.000315	0.000813	CcSEcCtD
Hydralazine—Nausea—Dactinomycin—kidney cancer	0.000313	0.000809	CcSEcCtD
Hydralazine—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000313	0.00355	CbGpPWpGaD
Hydralazine—Dizziness—Vincristine—kidney cancer	0.000312	0.000804	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000309	0.0035	CbGpPWpGaD
Hydralazine—Feeling abnormal—Paclitaxel—kidney cancer	0.000308	0.000796	CcSEcCtD
Hydralazine—Oedema—Capecitabine—kidney cancer	0.000307	0.000793	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—kidney cancer	0.000306	0.000789	CcSEcCtD
Hydralazine—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000304	0.000785	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—kidney cancer	0.000303	0.000781	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—kidney cancer	0.000302	0.000779	CcSEcCtD
Hydralazine—Thrombocytopenia—Capecitabine—kidney cancer	0.000301	0.000776	CcSEcCtD
Hydralazine—Tachycardia—Capecitabine—kidney cancer	0.0003	0.000774	CcSEcCtD
Hydralazine—Vomiting—Vincristine—kidney cancer	0.0003	0.000773	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000299	0.00339	CbGpPWpGaD
Hydralazine—Urticaria—Paclitaxel—kidney cancer	0.000297	0.000767	CcSEcCtD
Hydralazine—Rash—Vincristine—kidney cancer	0.000297	0.000767	CcSEcCtD
Hydralazine—Dermatitis—Vincristine—kidney cancer	0.000297	0.000766	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—kidney cancer	0.000296	0.000764	CcSEcCtD
Hydralazine—Body temperature increased—Paclitaxel—kidney cancer	0.000296	0.000764	CcSEcCtD
Hydralazine—Headache—Vincristine—kidney cancer	0.000295	0.000762	CcSEcCtD
Hydralazine—Anorexia—Capecitabine—kidney cancer	0.000293	0.000756	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—kidney cancer	0.00029	0.000748	CcSEcCtD
Hydralazine—Hypotension—Capecitabine—kidney cancer	0.000287	0.000741	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—kidney cancer	0.000284	0.000734	CcSEcCtD
Hydralazine—Rash—Gemcitabine—kidney cancer	0.000282	0.000727	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—kidney cancer	0.000282	0.000727	CcSEcCtD
Hydralazine—Headache—Gemcitabine—kidney cancer	0.00028	0.000723	CcSEcCtD
Hydralazine—Nausea—Vincristine—kidney cancer	0.00028	0.000722	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.00028	0.000722	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—kidney cancer	0.000279	0.000719	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—kidney cancer	0.000277	0.000716	CcSEcCtD
Hydralazine—Paraesthesia—Capecitabine—kidney cancer	0.000276	0.000712	CcSEcCtD
Hydralazine—Hypersensitivity—Paclitaxel—kidney cancer	0.000276	0.000712	CcSEcCtD
Hydralazine—Dyspnoea—Capecitabine—kidney cancer	0.000274	0.000707	CcSEcCtD
Hydralazine—Dyspepsia—Capecitabine—kidney cancer	0.00027	0.000698	CcSEcCtD
Hydralazine—Decreased appetite—Capecitabine—kidney cancer	0.000267	0.000689	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—kidney cancer	0.000266	0.000685	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000265	0.000684	CcSEcCtD
Hydralazine—Pruritus—Paclitaxel—kidney cancer	0.000265	0.000683	CcSEcCtD
Hydralazine—Constipation—Capecitabine—kidney cancer	0.000263	0.000678	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—kidney cancer	0.000259	0.000668	CcSEcCtD
Hydralazine—Diarrhoea—Paclitaxel—kidney cancer	0.000256	0.000661	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—RAF1—kidney cancer	0.000256	0.0029	CbGpPWpGaD
Hydralazine—Feeling abnormal—Capecitabine—kidney cancer	0.000253	0.000653	CcSEcCtD
Hydralazine—Chills—Doxorubicin—kidney cancer	0.00025	0.000645	CcSEcCtD
Hydralazine—Dizziness—Paclitaxel—kidney cancer	0.000248	0.000639	CcSEcCtD
Hydralazine—Urticaria—Capecitabine—kidney cancer	0.000244	0.00063	CcSEcCtD
Hydralazine—Body temperature increased—Capecitabine—kidney cancer	0.000243	0.000627	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000243	0.00275	CbGpPWpGaD
Hydralazine—Vomiting—Paclitaxel—kidney cancer	0.000238	0.000614	CcSEcCtD
Hydralazine—Rash—Paclitaxel—kidney cancer	0.000236	0.000609	CcSEcCtD
Hydralazine—Dermatitis—Paclitaxel—kidney cancer	0.000236	0.000609	CcSEcCtD
Hydralazine—Headache—Paclitaxel—kidney cancer	0.000234	0.000605	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—kidney cancer	0.000233	0.000602	CcSEcCtD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000231	0.00262	CbGpPWpGaD
Hydralazine—Hypersensitivity—Capecitabine—kidney cancer	0.000226	0.000584	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—kidney cancer	0.000225	0.000581	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—kidney cancer	0.000224	0.000579	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—kidney cancer	0.000223	0.000575	CcSEcCtD
Hydralazine—Nausea—Paclitaxel—kidney cancer	0.000222	0.000574	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—kidney cancer	0.000219	0.000565	CcSEcCtD
Hydralazine—Pruritus—Capecitabine—kidney cancer	0.000217	0.000561	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—kidney cancer	0.000217	0.00056	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—kidney cancer	0.000214	0.000553	CcSEcCtD
Hydralazine—Diarrhoea—Capecitabine—kidney cancer	0.00021	0.000542	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—kidney cancer	0.000207	0.000533	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—kidney cancer	0.000207	0.000533	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—kidney cancer	0.000206	0.000531	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—kidney cancer	0.000204	0.000527	CcSEcCtD
Hydralazine—Dizziness—Capecitabine—kidney cancer	0.000203	0.000524	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—kidney cancer	0.000198	0.000511	CcSEcCtD
Hydralazine—Vomiting—Capecitabine—kidney cancer	0.000195	0.000504	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—kidney cancer	0.000194	0.0005	CcSEcCtD
Hydralazine—Rash—Capecitabine—kidney cancer	0.000194	0.0005	CcSEcCtD
Hydralazine—Dermatitis—Capecitabine—kidney cancer	0.000193	0.000499	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—kidney cancer	0.000193	0.000499	CcSEcCtD
Hydralazine—Headache—Capecitabine—kidney cancer	0.000192	0.000497	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—kidney cancer	0.000189	0.000487	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—kidney cancer	0.000185	0.000477	CcSEcCtD
Hydralazine—Nausea—Capecitabine—kidney cancer	0.000182	0.000471	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00018	0.000466	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—kidney cancer	0.000178	0.000459	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—kidney cancer	0.000177	0.000456	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—kidney cancer	0.000174	0.00045	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—kidney cancer	0.000172	0.000444	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000171	0.000441	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.00017	0.00193	CbGpPWpGaD
Hydralazine—Constipation—Doxorubicin—kidney cancer	0.000169	0.000437	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.000167	0.00189	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000164	0.00186	CbGpPWpGaD
Hydralazine—Feeling abnormal—Doxorubicin—kidney cancer	0.000163	0.000421	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—kidney cancer	0.000157	0.000406	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—kidney cancer	0.000157	0.000404	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—kidney cancer	0.000146	0.000376	CcSEcCtD
Hydralazine—Pruritus—Doxorubicin—kidney cancer	0.00014	0.000362	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—kidney cancer	0.000135	0.00035	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000135	0.00153	CbGpPWpGaD
Hydralazine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000133	0.00151	CbGpPWpGaD
Hydralazine—Dizziness—Doxorubicin—kidney cancer	0.000131	0.000338	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—kidney cancer	0.000126	0.000325	CcSEcCtD
Hydralazine—Rash—Doxorubicin—kidney cancer	0.000125	0.000322	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—kidney cancer	0.000125	0.000322	CcSEcCtD
Hydralazine—Headache—Doxorubicin—kidney cancer	0.000124	0.00032	CcSEcCtD
Hydralazine—Nausea—Doxorubicin—kidney cancer	0.000118	0.000304	CcSEcCtD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.00011	0.00124	CbGpPWpGaD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000101	0.00114	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTT1—kidney cancer	9.64e-05	0.00109	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—PTGS1—kidney cancer	9.03e-05	0.00102	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	8.17e-05	0.000926	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTP1—kidney cancer	6.68e-05	0.000757	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	6.59e-05	0.000747	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—GSTM1—kidney cancer	6.14e-05	0.000696	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	6.05e-05	0.000686	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	5.82e-05	0.00066	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	5.74e-05	0.000651	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACY1—kidney cancer	5.12e-05	0.00058	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PDHB—kidney cancer	4.35e-05	0.000493	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—POMC—kidney cancer	4.34e-05	0.000492	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CCBL1—kidney cancer	4.09e-05	0.000464	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.55e-05	0.000402	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPAT—kidney cancer	3.55e-05	0.000402	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—FH—kidney cancer	3.3e-05	0.000374	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—APRT—kidney cancer	3.3e-05	0.000374	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GPC3—kidney cancer	3.1e-05	0.000352	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CA2—kidney cancer	3.02e-05	0.000342	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALAD—kidney cancer	2.94e-05	0.000333	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.87e-05	0.000325	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.8e-05	0.000318	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PGK1—kidney cancer	2.69e-05	0.000305	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.69e-05	0.000305	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—LDHB—kidney cancer	2.64e-05	0.000299	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CA9—kidney cancer	2.29e-05	0.000259	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CRABP1—kidney cancer	1.94e-05	0.00022	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ITPR2—kidney cancer	1.81e-05	0.000205	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACHE—kidney cancer	1.65e-05	0.000187	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTT1—kidney cancer	1.65e-05	0.000187	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SCARB1—kidney cancer	1.56e-05	0.000177	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS1—kidney cancer	1.54e-05	0.000175	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PSMD7—kidney cancer	1.51e-05	0.000172	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—BCHE—kidney cancer	1.44e-05	0.000163	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.42e-05	0.000161	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.37e-05	0.000155	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTP1—kidney cancer	1.14e-05	0.00013	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCB1—kidney cancer	1.08e-05	0.000123	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM1—kidney cancer	1.05e-05	0.000119	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYP1A1—kidney cancer	9.95e-06	0.000113	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—POMC—kidney cancer	7.42e-06	8.41e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—kidney cancer	5.92e-06	6.71e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—kidney cancer	5.16e-06	5.85e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.64e-06	4.13e-05	CbGpPWpGaD
